State of Wyoming Sells 6,578 Shares of DexCom, Inc. $DXCM

State of Wyoming decreased its holdings in DexCom, Inc. (NASDAQ:DXCM) by 69.2% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,930 shares of the medical device company’s stock after selling 6,578 shares during the quarter. State of Wyoming’s holdings in DexCom were worth $184,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Reflection Asset Management purchased a new stake in DexCom during the fourth quarter valued at approximately $25,000. Ascentis Independent Advisors bought a new position in DexCom in the 1st quarter worth $25,000. MCF Advisors LLC bought a new position in DexCom in the 4th quarter worth $32,000. DV Equities LLC purchased a new stake in DexCom in the 4th quarter worth $36,000. Finally, Spire Wealth Management increased its stake in DexCom by 113.8% in the 4th quarter. Spire Wealth Management now owns 573 shares of the medical device company’s stock worth $38,000 after buying an additional 305 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors.

Key Headlines Impacting DexCom

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Quarterly beat and higher outlook: DexCom reported adjusted earnings of $0.70 per share versus the $0.61 consensus, while revenue rose 13.1% year over year to $1.31 billion, exceeding estimates of $1.29 billion. Management raised its 2026 revenue outlook to approximately $5.18 billion-$5.25 billion, supported by strong global demand and broader product access. Reuters article
• Positive Sentiment: Product and market expansion: Growth is being supported by the G7 15 Day continuous glucose monitor, with DexCom targeting nearly 50% U.S. conversion by year-end, as well as expanded access and continued international growth. Margin improvement also contributed to a more constructive 2026 earnings narrative. Seeking Alpha article
• Positive Sentiment: Broad analyst support: Mizuho raised its price target to $95, Royal Bank of Canada and Wells Fargo lifted targets to $90, and UBS reaffirmed a Buy rating with a $96 target. Benchmark also reaffirmed Buy, although its $82 target is below the referenced trading level. Benzinga analyst updates
• Neutral Sentiment: Mixed valuation signals: JPMorgan raised its target substantially to $82 but retained a Neutral rating, indicating that some analysts view much of the improved outlook as already reflected in the stock.
• Negative Sentiment: Insider selling: Quiver Quantitative data shows 14 insider sales and no purchases during the past six months. This is a potential cautionary signal, although it has not outweighed the earnings-driven optimism. Quiver Quantitative analysis

Insider Activity at DexCom

In other DexCom news, Director Bridgette P. Heller sold 1,012 shares of DexCom stock in a transaction that occurred on Tuesday, May 12th. The stock was sold at an average price of $60.01, for a total value of $60,730.12. Following the sale, the director owned 25,007 shares of the company’s stock, valued at $1,500,670.07. The trade was a 3.89% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Mark G. Foletta sold 4,000 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $74.13, for a total value of $296,520.00. Following the sale, the director directly owned 52,852 shares in the company, valued at $3,917,918.76. This trade represents a 7.04% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 98,506 shares of company stock valued at $7,205,258 in the last 90 days. 0.28% of the stock is currently owned by insiders.

DexCom Stock Up 12.0%

Shares of DXCM stock opened at $83.45 on Friday. The company’s fifty day simple moving average is $73.14 and its two-hundred day simple moving average is $69.20. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $87.00. The stock has a market cap of $32.20 billion, a P/E ratio of 32.98, a PEG ratio of 1.23 and a beta of 1.45. The company has a quick ratio of 1.64, a current ratio of 1.95 and a debt-to-equity ratio of 0.42.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, July 30th. The medical device company reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.61 by $0.09. DexCom had a return on equity of 35.34% and a net margin of 20.12%.The firm had revenue of $1.31 billion during the quarter, compared to analyst estimates of $1.29 billion. During the same quarter last year, the business posted $0.48 earnings per share. The business’s quarterly revenue was up 13.1% compared to the same quarter last year. Analysts predict that DexCom, Inc. will post 2.57 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on DXCM. JPMorgan Chase & Co. boosted their price objective on DexCom from $65.00 to $82.00 and gave the company a “neutral” rating in a research report on Friday. Weiss Ratings cut DexCom from a “hold (c)” rating to a “hold (c-)” rating in a research report on Tuesday. Robert W. Baird set a $105.00 target price on DexCom in a research note on Friday. UBS Group set a $96.00 target price on DexCom and gave the company a “buy” rating in a research note on Tuesday. Finally, Stifel Nicolaus set a $95.00 price target on DexCom and gave the stock a “buy” rating in a report on Friday. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, DexCom currently has a consensus rating of “Moderate Buy” and an average target price of $88.12.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.